Ascidian Therapeutics
MA - BostonBiotechnology
Focus: Ascidian Therapeutics is a Boston-based biotechnology company focused on mutated exon replacement gene therapy, operating in early-stage development with a single Phase 1/2 program targeting rare genetic diseases.
Profile data last refreshed 3h ago · AI intelligence enriched 3w ago
Open Jobs
1
Should You Work at Ascidian Therapeutics?
AI assessmentAscidian represents a high-risk, early-stage gene therapy opportunity best suited for scientists and translational specialists willing to bet on a focused platform with minimal current hiring momentum.
Why Work Here
- Early-stage gene therapy platform with novel mutated exon replacement mechanism offers opportunity to build foundational IP and scientific expertise in an emerging modality
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
ACDN-01
Stargardt DiseaseClinical Trials (2)
NCT06467344Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)
Phase 1/2Help build intelligence for Ascidian Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.